Anonymous Client D — Biopharma company with Phase II cardiovascular asset targeting heart failure
The heart failure treatment landscape had evolved dramatically with the approval of SGLT2 inhibitors and ARNIs, raising the standard of care and complicating trial design for new entrants. The client's asset had a novel mechanism but needed to demonstrate efficacy against a now-higher standard of care. Their proposed trial design used a composite endpoint that had been successful 5 years ago but had not been used in the 4 most recent heart failure approvals. Additionally, their site selection strategy focused on traditional cardiovascular trial centers without considering the shifting site landscape.
A biopharma company with a Phase II cardiovascular asset targeting heart failure needed to benchmark their proposed Phase III trial design against 40+ competing programs. Their current design had a projected enrollment timeline of 42 months, a composite primary endpoint that had not been used in recent approvals, and no clear competitive positioning relative to 4 drugs that had launched in the same indication in the past 3 years. The CMO was concerned that the trial design would result in a 6-12 month delay to market entry.
We conducted a comprehensive competitive trial benchmarking analysis across 40+ active and completed cardiovascular trials. Our analysis covered trial design elements (endpoints, sample size, duration, randomization), enrollment strategies (site selection, patient recruitment, competitive enrollment), and competitive positioning (differentiation from recent approvals, regulatory precedent). We delivered actionable recommendations to optimize trial design, accelerate enrollment, and strengthen regulatory submission positioning.
Trial design benchmarking: Analyzed 40+ cardiovascular trials from ClinicalTrials.gov and regulatory databases, comparing endpoints, sample sizes, durations, and statistical approaches
Endpoint optimization analysis: Evaluated primary endpoint choices across recent heart failure approvals, regulatory guidance documents, and FDA/EMA precedent
Enrollment modeling: Built enrollment forecasting models based on historical site performance, patient pool availability, and competing trial recruitment
Site selection optimization: Analyzed 500+ cardiovascular trial sites for enrollment performance, patient diversity, and competitive trial density
Regulatory precedent mapping: Reviewed FDA and EMA approval packages for 4 recent heart failure drugs to understand regulatory expectations
Competitive positioning analysis: Assessed how the client's trial design would differentiate from and build upon recent approvals
We recommended 6 specific trial design modifications that collectively reduced projected enrollment time by 10 months and aligned the primary endpoint with current regulatory expectations. Key changes included: (1) switching to a hierarchical composite endpoint used in 3 of the last 4 approvals, (2) expanding site network from 120 to 180 sites with focus on high-enrollment emerging market sites, (3) adding a pre-specified subgroup analysis aligned with FDA diversity guidance, (4) implementing an adaptive interim analysis at 50% enrollment, (5) revising the statistical analysis plan to align with recent regulatory precedent, and (6) developing a competitive enrollment mitigation plan for sites with competing trials.
Phase 1 (Weeks 1-3): Competitive trial landscape analysis across 40+ cardiovascular programs
Phase 2 (Weeks 3-6): Endpoint optimization and regulatory precedent analysis
Phase 3 (Weeks 5-8): Enrollment modeling and site selection optimization
Phase 4 (Weeks 7-10): Statistical analysis plan review and competitive positioning strategy
Phase 5 (Weeks 10-12): Final recommendations, protocol amendment support, and regulatory meeting preparation
| Metric | Before | After | Impact |
|---|---|---|---|
| Projected Enrollment Timeline | 42 months | 32 months | 10-month acceleration through site expansion and enrollment optimization |
| Primary Endpoint Alignment | Outdated composite | Hierarchical composite (current standard) | Aligned with 3 of last 4 FDA approvals in heart failure |
| Site Network | 120 sites (traditional only) | 180 sites (including emerging markets) | +50% site capacity with 35% cost reduction per patient |
| Patient Diversity | No diversity plan | Pre-specified subgroup analysis | Aligned with FDA diversity guidance, strengthening submission |
| Regulatory Meeting Outcome | No meeting scheduled | FDA Type C meeting aligned | Pre-submission alignment on trial design modifications |
“We were about to start a 42-month trial with an endpoint that the FDA hadn't accepted in 4 years. Medifirm's analysis showed us exactly what recent approvals used and why. The 10 months we saved in enrollment translated to $180M in additional revenue from earlier market entry.”
Chief Medical Officer
Anonymous Client D
Forecast
Optimized trial design and site selection projected to reduce time-to-readout by 10 months, enabling earlier regulatory submission and market entry worth $180M+ in additional revenue.
Every engagement starts with understanding your unique strategic challenge. Partner with Medifirm to transform data into decisions.